Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 55.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,875 shares of the biopharmaceutical company’s stock after purchasing an additional 29,590 shares during the period. Intra-Cellular Therapies makes up approximately 1.4% of Lisanti Capital Growth LLC’s holdings, making the stock its 23rd largest holding. Lisanti Capital Growth LLC’s holdings in Intra-Cellular Therapies were worth $5,676,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Kapitalo Investimentos Ltda purchased a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth about $26,000. Headlands Technologies LLC acquired a new stake in Intra-Cellular Therapies in the first quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $53,000. Summit Securities Group LLC acquired a new position in shares of Intra-Cellular Therapies during the second quarter worth $56,000. Finally, Cape Investment Advisory Inc. purchased a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at $78,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Mizuho lifted their price target on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. Cantor Fitzgerald increased their price target on Intra-Cellular Therapies from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, August 8th. The Goldman Sachs Group dropped their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Canaccord Genuity Group increased their target price on Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Finally, UBS Group cut their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.00.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $72.84, for a total value of $2,505,404.64. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $77,962,764.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Sharon Mates sold 34,396 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Nostrand Robert L. Van sold 20,000 shares of the business’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $75.91, for a total transaction of $1,518,200.00. Following the sale, the director now owns 9,690 shares in the company, valued at $735,567.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 199,778 shares of company stock worth $14,892,738. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Stock Up 1.4 %

Shares of NASDAQ:ITCI traded up $1.02 on Friday, reaching $73.28. 603,112 shares of the company’s stock were exchanged, compared to its average volume of 599,306. Intra-Cellular Therapies, Inc. has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The business’s 50-day moving average is $74.95 and its two-hundred day moving average is $71.19.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company had revenue of $161.40 million during the quarter, compared to analyst estimates of $157.74 million. During the same period in the prior year, the company earned ($0.45) earnings per share. The business’s revenue was up 45.7% compared to the same quarter last year. Equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.